Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers

Vaccine

Volumn 28, Issue 3, 2010, Pages 707-713

  Bumann, Dirk ^a   Behre, Christoph ^b   Behre, Katharina ^b   Herz, Steffen ^b   Gewecke, Britta ^a   Gessner, J Engelbert ^a   von Specht, Bernd Ulrich ^b   Baumann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CVD908; Mucosal vaccines; Nasal vaccination; OprF OprI; Oral vaccination; Pseudomonas vaccine; Ty21a

Indexed keywords

BACTERIAL VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN F; OUTER MEMBRANE PROTEIN I; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AIRWAY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VACCINATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GENETIC VECTORS; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYSTEM; SALMONELLA; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 71149111219     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.080     Document Type: Article

References (32)

1. Doring G., Meisner C., and Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 104 26 (2007) 11020-11025
2. Doring G., and Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26 8 (2008) 1011-1024
3. Zuercher A.W., Horn M.P., Que J.U., Ruedeberg A., Schoeni M.H., Schaad U.B., et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 47 2 (2006) 302-308
4. Rudin A., Riise G.C., and Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun 67 6 (1999) 2884-2890
5. Kunkel E.J., and Butcher E.C. Plasma-cell homing. Nat Rev Immunol 3 10 (2003) 822-829
6. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine (2006)
7. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (2005) S45-S53
8. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines 7 8 (2008) 1257-1276
9. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 7 (2007) 685-696
10. Huo Z., Sinha R., McNeela E.A., Borrow R., Giemza R., Cosgrove C., et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect Immun 73 12 (2005) 8256-8265
11. Zuercher A.W., Horn M.P., Wu H., Song Z., Bundgaard C.J., Johansen H.K., et al. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 24 20 (2006) 4333-4342
12. Thomas L.D., Kyd J.M., Bastin D.A., Dunkley M.L., and Cripps A.W. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 37 2-3 (2003) 155-160
13. Abraham E., and Shah S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 149 11 (1992) 3719-3726
14. Priebe G.P., Meluleni G.J., Coleman F.T., Goldberg J.B., and Pier G.B. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun 71 3 (2003) 1453-1461
15. Buret A., Dunkley M.L., Pang G., Clancy R.L., and Cripps A.W. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha. Infect Immun 62 12 (1994) 5335-5343
16. Thomas L.D., Cripps A.W., and Kyd J.M. Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection. Vaccine (2009)
17. Baumann U., Mansouri E., and von Specht B.U. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 22 7 (2004) 840-847
18. Baumann U., Gocke K., Gewecke B., Freihorst J., and von Specht B.U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 8 (2007) 57
19. Gocke K., Baumann U., Hagemann H., Gabelsberger J., Hahn H., Freihorst J., et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 37 2-3 (2003) 167-171
20. Knapp B., Hundt E., Lenz U., Hungerer K.D., Gabelsberger J., Domdey H., et al. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 17 13-14 (1999) 1663-1666
21. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 67 3 (1999) 1461-1470
22. Larbig M., Mansouri E., Freihorst J., Tümmler B., Köhler G., Domdey H., et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19 17-19 (2001) 2291-2297
23. Mansouri E., Blome-Eberwein S., Gabelsberger J., Germann G., and von Specht B.U. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol Med Microbiol 37 2-3 (2003) 161-166
24. Arnold H., Bumann D., Felies M., Gewecke B., Sörensen M., Gessner J.E., et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect Immun 72 11 (2004) 6546-6553
25. Aebischer T., Bumann D., Epple H.J., Metzger W., Schneider T., Cherepnev G., et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57 8 (2008) 1065-1072
26. Bumann D., Metzger W.G., Mansouri E., Palme O., Wendland M., Hurwitz R., et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20 5-6 (2001) 845-852
27. Mutharia L.M., Nicas T.I., and Hancock R.E. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 146 6 (1982) 770-779
28. von Specht B.U., Gabelsberger J., Knapp B., Hundt E., Schmidt-Pilger H., Bauernsachs S., et al. Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections. J Biotechnol 83 1-2 (2000) 3-12
29. Bumann D., Hueck C., Aebischer T., and Meyer T.F. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol Med Microbiol 27 4 (2000) 357-364
30. Bumann D. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses. Infect Immun 69 12 (2001) 7493-7500
31. Pier G.B., Grout M., Zaidi T., Meluleni G., Mueschenborn S.S., Banting G., et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393 6680 (1998) 79-82
32. Pasetti M.F., Pickett T.E., Levine M.M., and Sztein M.B. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18 28 (2000) 3208-3213